| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The primary target of MC-Val-Cit-PAB-rifabutin, as an ADC drug-linker conjugate, is the specific antigen expressed on the surface of target cells (typically cancer cells), to which the antibody component of the ADC binds. The cytotoxic payload, rifabutin, is a DNA-dependent RNA polymerase inhibitor. Upon binding of the ADC to the target antigen, the conjugate is internalized, and the linker is cleaved to release rifabutin, which then inhibits RNA polymerase and kills the target cell. The MC-Val-Cit-PAB linker is designed to be cleaved by cathepsins in the lysosome, ensuring selective release of the payload inside target cells.
|
|---|---|
| ln Vitro |
In vitro studies of MC-Val-Cit-PAB-rifabutin are focused on evaluating its cytotoxicity against target cells and its stability in biological fluids. As an ADC drug-linker conjugate, the compound's activity is typically assessed in cell-based cytotoxicity assays using target antigen-positive and antigen-negative cell lines. The conjugate is expected to show potent antitumor activity against target-positive cells while sparing antigen-negative cells. The compound's stability in plasma and its ability to release rifabutin upon internalization are also evaluated. MC-Val-Cit-PAB-rifabutin is used to construct ADCs that are effective and stable in vitro.
|
| ln Vivo |
In vivo studies of MC-Val-Cit-PAB-rifabutin are focused on evaluating the antitumor efficacy and pharmacokinetics of ADCs constructed with this drug-linker conjugate. The compound is used to build ADCs that are effective and stable in vivo. In xenograft models, ADCs containing MC-Val-Cit-PAB-rifabutin are expected to show potent antitumor activity with improved pharmacokinetics and a better therapeutic index compared to unconjugated rifabutin. The quaternary ammonium-based bioreversible linker improves the pharmacokinetics and therapeutic index of the payload. Further studies are needed to fully characterize the in vivo efficacy and safety of ADCs containing this drug-linker conjugate.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, MC-Val-Cit-PAB-rifabutin is not typically used in direct binding assays, as it is a drug-linker conjugate rather than a small molecule drug. However, the stability of the linker and the release of rifabutin can be assessed in vitro using enzymatic or chemical cleavage assays. The compound is incubated with cathepsins or other lysosomal enzymes, and the release of rifabutin is quantified by HPLC or LC-MS. The binding of the ADC to its target antigen is typically assessed using the full ADC construct, not the drug-linker conjugate alone. Standard assay conditions include physiological buffer systems with appropriate pH to mimic the lysosomal environment.
|
| Cell Assay |
For in vitro cellular experiments, MC-Val-Cit-PAB-rifabutin is typically evaluated as part of a complete ADC. The ADC is tested in target antigen-positive and antigen-negative cell lines to assess target-specific cytotoxicity. Cells are cultured in appropriate media and treated with various concentrations of the ADC. Cell viability is assessed using MTT, CellTiter-Glo, or other cytotoxicity assays. The selectivity of the ADC for target-positive cells is a key measure of its therapeutic potential. Internalization of the ADC and release of rifabutin can be assessed using fluorescently labeled antibodies or by measuring free rifabutin in cell lysates. The compound's stability in cell culture medium is monitored.
|
| Animal Protocol |
For in vivo animal experiments, MC-Val-Cit-PAB-rifabutin is used to construct ADCs that are administered to tumor-bearing mice. Xenograft models using human cancer cell lines that express the target antigen are commonly used. The ADC is typically administered via intravenous injection at various doses and schedules. Tumor volume is measured regularly, and tumor growth inhibition is calculated. Pharmacokinetic studies are performed to measure the levels of ADC, total antibody, and released rifabutin in plasma. Tissue distribution studies may also be conducted. Body weight and overall health are monitored as indicators of tolerability. The improved pharmacokinetics and therapeutic index of the ADC are key outcomes of these studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of MC-Val-Cit-PAB-rifabutin as a drug-linker conjugate are improved compared to unconjugated rifabutin due to the targeted delivery provided by the ADC. The quaternary ammonium-based bioreversible linker enhances the pharmacokinetics and therapeutic index of the payload. When administered as part of an ADC, the conjugate is expected to have a longer half-life in circulation and improved tumor accumulation compared to the free drug. The release of rifabutin from the linker is designed to occur preferentially inside target cells, reducing systemic exposure and toxicity. Detailed pharmacokinetic parameters would depend on the specific ADC construct and the target antigen.
|
| Toxicity/Toxicokinetics |
Toxicological data for MC-Val-Cit-PAB-rifabutin are limited, as it is a research tool for ADC development. The toxicity of ADCs containing this drug-linker conjugate would depend on the target antigen expression profile, the potency of rifabutin, and the stability of the linker. Rifabutin, as a macrolide antibiotic and RNA polymerase inhibitor, has a known safety profile, but its use as an ADC payload may have different toxicological considerations. Off-target toxicity could occur if the ADC is not sufficiently selective or if the linker releases rifabutin prematurely. Appropriate safety precautions should be taken when handling this compound, including the use of personal protective equipment and adherence to institutional safety guidelines.
|
| References | |
| Additional Infomation |
MC-Val-Cit-PAB-rifabutin is a research compound used for ADC development. No clinical trials or regulatory approvals have been reported for this specific drug-linker conjugate as a therapeutic agent. It is available from various chemical suppliers for research purposes only. The compound is a quaternary ammonium-based bioreversible drug linker used for targeted delivery, improving pharmacokinetics and the therapeutic index. It is used to construct ADCs that are effective and stable in vitro and in vivo. MC-Val-Cit-PAB-rifabutin features the potent antitumor agent rifabutin (a DNA-dependent RNA polymerase inhibitor) connected via the MC-Val-Cit-PAB ADC linker.
|
| Molecular Formula |
C74H101N10O17
|
|---|---|
| Molecular Weight |
1402.65
|
| Exact Mass |
1401.734
|
| CAS # |
2055900-34-8
|
| PubChem CID |
168434363
|
| Appearance |
Brown to reddish brown solid powder
|
| LogP |
6.1
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
101
|
| Complexity |
3270
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
O=C1[C@]2(OC=C[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@@H](O)[C@@H](C)C=CC=C(C)C(=O)NC3C(=O)C4C(O)=C(C)C(O2)=C1C=4C1=NC2(CC[N+](CC(C)C)(CC4C=CC(NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN5C(C=CC5=O)=O)=CC=4)CC2)NC1=3)C)O)C)OC(=O)C)C)OC)C |c:18,51,82,87,t:4,16,29,89|
|
| InChi Key |
WBLRGFPDBLJWGU-QDTCKSFQSA-O
|
| InChi Code |
InChI=1S/C74H100N10O17/c1-39(2)37-84(38-48-23-25-49(26-24-48)77-70(95)50(21-18-32-76-72(75)97)78-71(96)58(40(3)4)79-52(86)22-15-14-16-33-83-53(87)27-28-54(83)88)34-30-74(31-35-84)81-59-55-56-64(91)46(10)67-57(55)68(93)73(12,101-67)99-36-29-51(98-13)43(7)66(100-47(11)85)45(9)63(90)44(8)62(89)41(5)19-17-20-42(6)69(94)80-61(65(56)92)60(59)82-74/h17,19-20,23-29,36,39-41,43-45,50-51,58,62-63,66,89-90H,14-16,18,21-22,30-35,37-38H2,1-13H3,(H8-,75,76,77,78,79,80,81,82,86,87,88,91,92,93,94,95,96,97)/p+1/b19-17-,36-29-,42-20-/t41-,43+,44+,45+,50-,51-,58-,62-,63+,66+,73-,74?,84?/m0/s1
|
| Chemical Name |
[(7S,9Z,11S,12R,13S,14R,15R,16R,17S,18S,19Z,21Z)-1'-[[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl]-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(31),2,4,9,19,21,25(32),26,29-nonaene-28,4'-piperidin-1-ium]-13-yl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20 mg/mL (~13.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7129 mL | 3.5647 mL | 7.1294 mL | |
| 5 mM | 0.1426 mL | 0.7129 mL | 1.4259 mL | |
| 10 mM | 0.0713 mL | 0.3565 mL | 0.7129 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
